Geron (GERN) Corporate presentation summary

Strategic vision and financial outlook

• Targeting leadership in hematology by maximizing RYTELO (imetelstat), a first-in-class telomerase inhibitor, with projected 2026 net product revenue of $220M–$240M and operating expenses of $230M–$240M.

• Commercial strategy includes expanding RYTELO into relapsed/refractory myelofibrosis (R/R MF) pending Phase 3 ImpactMF trial results and aligning on EU LR-MDS strategy by end of 2026.

• Financial discipline and innovation are emphasized, leveraging a strong balance sheet to pursue new opportunities.

RYTELO clinical profile and market positioning

• RYTELO is approved in the U.S. and EU for lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia, offering a unique mechanism targeting telomerase in malignant cells.

• Demonstrated higher and durable transfusion independence (39.8% ≥8-week TI vs 15% placebo, median response 52 weeks) and manageable safety profile with predictable cytopenias.

• NCCN guidelines recommend imetelstat as a preferred second-line treatment and as an option in first-line ESA-ineligible patients.

Commercial execution and performance

• Q1 2026 net revenue reached $51.8M, up 31% year-over-year, with a 6% demand increase over the previous quarter and ~1,450 ordering accounts since approval.

• About 33% of new patient starts are in first and second line, reflecting growing adoption in targeted segments.

• Coordinated commercial, medical, and advocacy efforts focus on expanding awareness, confidence, and appropriate use of RYTELO.